Frederick Sweet, Ph.D.

Title:
Professor, Department of Obstetrics and Gynecology

Education:
PhD University of Alberta, Canada

Residency:
Sloan-Kettering Institute for Cancer Research, Rye, NY.

Fellowship:
Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS.
Career Development Award, National Institutes of Health Research

Research Publications:
Sweet F.  Response to the article entitled "a recent exposure to mustard gas in the United States:  clinical findings of a cohort (n = 247) 6 years after exposure.”
MedGenMed. 2005, 7 (1): 46

Magyar A, Szendi Z, Forgo P, Mak M, Gorls H, Sweet F.   Stereoselective reactions of (20R)-3,20-dihydroxy- (3',4'-dihydro-2'H-pyranyl)-5-pregnene derivatives form 27-nor-3,20,23,26-tetrahydroxy-cholesten-22-onesand related bromo ketones.
Steroids. 2004, 69(1): 35-42.

Sweet F.    Low-Cost "Vacuum Desiccator.  J. Chem. Educ. 2004, 81: 1500.

Chen Q, Zhang J, Sweet F.  Homology of primate DNA fragments for estrous-associated oviductal glycoprotein.  Hereditas. 2003; 139(1): 75-9.

Szendi Z, Forgo P, Tasi G, Bocskei Z, Nyerges L, Sweet F.  1,5-Hydride shift in Wolff-Kishner reduction of (20R)-3beta, 20, 26-trihydroxy-27-norcholest-5-en-22-one: synthetic, quantum chemical, and NMR studies.  Steroids. 2002, 67(1): 31-8.

Chen Q, Adler S, Sweet F.  Gene Expression and Intermolecular Forces in Estrogen/Receptor Binding.  Proceedings of the 10th International Congress on Genes, Gene Families, and Isozymes.  October 5-10, 1999.

Since joining the School of Medicine in July 1971, Prof. Sweet carried out research in chemical synthesis and biochemistry associated with steroid biosynthesis, transport, metabolism and mechanisms of action for biomedical research on birth control. Similarly, he has applied chemical synthesis of new chemotherapeutic agents, more recently immuno cytotoxins, for treating breast and ovarian cancers. Among the more novel substances first made by Sweet were boronated estrogens for treating breast cancers with low energy neutron beams, and also Taxol-CA125 antibody conjugates for selectively killing ovarian cancers. His biomedical research projects during nearly four decades were carried out in collaboration with research laboratories in England, France, The Netherlands, Hungary (before and after the Cold War), Australia, and China. Sweet co-founded the medical school’s Office of Environmental Health and Safety, during five years chaired the department’s Research Division, served for twenty years on the Committee for Medical School Admissions, and he is currently serving his second term on the Disclosure Review Committee (managing financial conflicts of interest).  He also had served two terms on the NIH Reproductive Endocrinology Study Section.  He has served on the editorial board of Endocrine Reviews, continues to serve in his twnety first year on the editorial board of the international journal Steroids, and this year he was invited to join the editorial board of Biologics: Targets & Therapy.